Manas Kumar Sahoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Manas Kumar Sahoo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chandrasekhar Bal
Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
2 shared publications Smeeta Gajendra
Department of Pathology & Lab Medicine, Medanta-The Medicity, Gurugram, Haryana, India
2 shared publicationsAll India Institute of Medical Sciences (AIIMS)
1 shared publication- Geetanjali Arora
Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
1 shared publication Kulbir Ahlawat
Radiology
1 shared publication- Madhavi Tripathi
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
1 shared publication
Latest Publications
- 1 September 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (9) , 679-681
Schmorl's Node: Confusion Still Persists in 68Ga-Prostate-Specific Membrane Antigen Ligand PET/CT
Ga-68-prostate-specific membrane antigen (PSMA) ligand PET/CT is commonly believed to be prostate specific as the name itself suggests. However, PSMA-expressing nonprostatic cancers as well as benign lesions are continuously being added to the list. We reported PSMA-expressing Schmorl's node in L1 vertebra of a 74-year-old man with prostate cancer. Prostate-specific membrane antigen expression in the vertebral lesion raised a metastatic suspicion. However, on analysis of previous CT scan done 2 years before, the same lesion was observed with no significant interval change, confirming its benign nature. With more use of PSMA ligand PET/CT, more limitations and false positivities will be explored.
- 1 September 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (9) , 679-681
Schmorl's Node: Confusion Still Persists in 68Ga-Prostate-Specific Membrane Antigen Ligand PET/CT
Ga-68-prostate-specific membrane antigen (PSMA) ligand PET/CT is commonly believed to be prostate specific as the name itself suggests. However, PSMA-expressing nonprostatic cancers as well as benign lesions are continuously being added to the list. We reported PSMA-expressing Schmorl's node in L1 vertebra of a 74-year-old man with prostate cancer. Prostate-specific membrane antigen expression in the vertebral lesion raised a metastatic suspicion. However, on analysis of previous CT scan done 2 years before, the same lesion was observed with no significant interval change, confirming its benign nature. With more use of PSMA ligand PET/CT, more limitations and false positivities will be explored.
- Open Access
- 1 October 2017
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 16 (04) , 338-339
68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography: How much specific it is?
- 1 October 2017
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 16 (04) , 338-339
Open Access68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography: How much specific it is?
- Open Access
- 1 July 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (03) , 219-220
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
- 1 July 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (03) , 219-220
Open AccessUse of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
- Open Access
- 1 July 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (03) , 218
A case of lingual thyroid presenting with severe hematemesis in pregnancy
- 1 July 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (03) , 218
Open AccessA case of lingual thyroid presenting with severe hematemesis in pregnancy
- Open Access
- 14 May 2016
- Published by Herald Scholarly Open Access in Journal of Nuclear Medicine Radiology & Radiation Therapy
- Vol. 1 (1) , 1-2
18F-FDG-PET/CT Imaging in Leukemia
Positron Emission Tomography/Computed Tomography (PET/CT) is a noninvasive radionuclide-based whole body imaging technique which combines both a Positron Emission Tomography (PET) scanner and an x-ray Computed Tomography (CT) scanner in a single gantry system.
- 14 May 2016
- Published by Herald Scholarly Open Access in Journal of Nuclear Medicine Radiology & Radiation Therapy
- Vol. 1 (1) , 1-2
Open Access18F-FDG-PET/CT Imaging in Leukemia
Positron Emission Tomography/Computed Tomography (PET/CT) is a noninvasive radionuclide-based whole body imaging technique which combines both a Positron Emission Tomography (PET) scanner and an x-ray Computed Tomography (CT) scanner in a single gantry system.
- 22 March 2016
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 50 (4) , 344-347
Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule
68Ga-Prostate specific membrane antigen- N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid- positron emission tomography/computed tomography or 68 Ga- HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN. Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.
- 22 March 2016
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 50 (4) , 344-347
Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule
68Ga-Prostate specific membrane antigen- N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid- positron emission tomography/computed tomography or 68 Ga- HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN. Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.
- 2 October 2013
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 31 (11) , 766-769
Pulmonary alveolar microlithiasis: imaging characteristics of planar and SPECT/CT bone scan versus 18F-FDG and 18F-sodium fluoride PET/CT scanning
Pulmonary alveolar microlithiasis (PAM) is a very rare disease in which multiple microscopic calcium phosphate microliths are deposited within the alveoli of both lungs. A lung biopsy is considered to be definitive for final diagnosis; however, non-invasive imaging modalities such as chest X-ray, HRCT scan and 99mTc-MDP bone scan suggest the diagnosis in the vast majority of patients. Although 18F-FDG PET/CT has been tried to characterize the disease, 18F-sodium fluoride PET/CT as a ‘proof-of-principle’ was tried for the first time in a known case of PAM in order to characterize the lung lesions. Interestingly, we noted that 18F-sodium fluoride PET/CT is a superior modality in characterization and assessment of the extent of disease in PAM compared to all other non-invasive imaging modalities. Thus, we recommend that 18F-sodium fluoride PET/CT should be the investigation of choice in PAM.
- 2 October 2013
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 31 (11) , 766-769
Pulmonary alveolar microlithiasis: imaging characteristics of planar and SPECT/CT bone scan versus 18F-FDG and 18F-sodium fluoride PET/CT scanning
Pulmonary alveolar microlithiasis (PAM) is a very rare disease in which multiple microscopic calcium phosphate microliths are deposited within the alveoli of both lungs. A lung biopsy is considered to be definitive for final diagnosis; however, non-invasive imaging modalities such as chest X-ray, HRCT scan and 99mTc-MDP bone scan suggest the diagnosis in the vast majority of patients. Although 18F-FDG PET/CT has been tried to characterize the disease, 18F-sodium fluoride PET/CT as a ‘proof-of-principle’ was tried for the first time in a known case of PAM in order to characterize the lung lesions. Interestingly, we noted that 18F-sodium fluoride PET/CT is a superior modality in characterization and assessment of the extent of disease in PAM compared to all other non-invasive imaging modalities. Thus, we recommend that 18F-sodium fluoride PET/CT should be the investigation of choice in PAM.